Tom van Meerten
dr.
I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.
Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.
Published in: Nature Communications
Access to document
10.1038/s41467-025-66767-9
document
Chimeric antigen receptor T-cell therapy (CART) has revolutionized the treatment of patients with refractory/relapsed large B-cell lymphoma (R/R LBCL). Limited biopsy data indicate that a higher activated CD8 + T-cell density is associated with tumor response. However, tumor biopsies fail to capture the systemic kinetics of CD8 + T-cells. Therefore, we conducted an exploratory phase 2 single-arm trial utilizing a zirconium-89-labeled one-armed anti-CD8α antibody ( 89ZED88082A) to enable whole-body imaging of CD8 + T-cells through positron emission tomography (PET) (NL9034; EUCTR2020-004749-35-NL). Imaging analysis was performed in 23 patients...
Janneke W de Boer, Kylie Keijzer, Jaap A van Doesum, Nienke A M Smit, Adrienne H Brouwers, Joyce van Sluis, Marjolijn N Lub-de Hooge, Frank R Pierik, Gerwin A Huls, Lisanne V van Dijk, Lydia Visser, Arjan Diepstra, Walter Noordzij, Simon P Williams, Alexander Ungewickell, Sjoerd G Elias, Elisabeth G E de Vries, Anne G H Niezink, Tom van Meerten
T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines
Published in: Haematologica
Access to document
10.3324/haematol.2024.287136
document
Cilia R. Pothast, Quincy Hofsink, Sabine Haggenburg, Romy C. Dijkland, Marian Van de Meent, Kayleigh Van Dijk, Michel S. Bhoekhan, Nienke J.E. Haverkate, Johan Van Meerloo, J. H.Frederik Falkenburg, Ruben A.L. De Groen, Annoek E.C. Broers, Jaap A. Van Doesum, Rob S. Van Binnendijk, Gerco Den Hartog, Birgit I. Lissenberg-Witte, Arnon P. Kater, Gaby P. Smits, Dorine Wouters, Ester M.M. Van LeeuwenHetty J. Bontkes, Neeltje A. Kootstra, Sandra Vogels-Nooijen, Debbie Van Baarle, Rory D. De Vries, Tom Van Meerten, Pim G.N.J. Mutsaers, Abraham Goorhuis, Inger S. Nijhof, Mette D. Hazenberg, Mirjam H.M. Heemskerk, Caroline E. Rutten, Cobra Kai Study Team
Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections and survival after CART in R/R LBCL
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2025016689
document
Early identification of patients at risk for immune effector cell-associated hematotoxicity (ICAHT) is essential to minimize non-relapse mortality. The CAR-HEMATOTOX (HT) score is an implemented risk-stratification tool for ICAHT, infections and survival in relapsed/refractory large B-cell lymphoma (R/R LBCL) patients receiving CAR T-cell therapy (CART). Although validated in its defining study, the HT score was developed in a small cohort, necessitating independent external validation. This study externally validates the HT score in a real-world population-based cohort of adults with R/R LBCL receiving CART. The HT score, based on...
Janneke W de Boer, Kylie Keijzer, Suzanne van Dorp, Pim G N J Mutsaers, Anne GH Niezink, Jaap A van Doesum, Yasmina Im Serroukh, Louise W Muntendam, Astrid E Pulles, Esther J Kret, Aniko Sijs-Szabo, Jesse Oomen, Astrid Mp Demandt, Wendy Bc Stevens, Maria T Kuipers, Elise Ra Pennings, Anne Mea Spanjaart, Marie José Kersten, Margot Jak, Lisanne Vania van DijkMarjolein Wm van der Poel, Joost Sp Vermaat, Tom van van Meerten
Real-World Accuracy of Continuous Glucose Monitoring During Intensive Hematological Care: A Prospective Study
Published in: Diabetes technology & therapeutics
Access to document
10.1089/dia.2025.0232
document
Background: Patients treated for a hematological malignancy are susceptible to hyperglycemia, which can negatively affect treatment outcomes. Therefore, close monitoring of glucose levels is crucial. Data demonstrated that capillary measurement methods underreport hyperglycemic episodes compared with continuous glucose monitoring (CGM). However, the accuracy of CGM during intensive hematological treatments, and the associated metabolic and hemostatic imbalances, is unknown, which we aim to investigate in the current study. Methods: For the analysis, data collected during a prospective study that compared CGM with capillary point-of-care (POC) glucose measurements in adult...
Marieke Tienstra, Riemer A Been, Janneke W de Boer, Reinold O B Gans, André P van Beek, Hilde A M Kooistra, Valerie R Wiersma, Omar G Mustafa, Pratik Choudhary, Tom van Meerten, Peter R van Dijk
K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies
Published in: Molecular therapy. Oncology
Access to document
10.1016/j.omton.2025.200988
document
Chimeric antigen receptor (CAR)-based therapy is of interest for relapsed or refractory (r/r) T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphomas. A prominent target antigen for this is the receptor CD7, which is expressed in ∼95% of T-ALL, ∼50% of peripheral T cell lymphomas, as well as 10% of acute myeloid leukemias. Here, we preclinically evaluated and compared CD7-targeted ligand K12-based CAR-T to an scFvCD7-based CAR-T construct. K12 CAR-T cells produced significantly higher interferon gamma (IFN-γ) after CD7 activation compared to scFv-CD7 CAR-T cells. Similarly, in...
Nienke Visser, Macarena González-Corrales, Jimena Álvarez-Freile, Maurien G Pruis, Lena Rockstein, Harm Jan Lourens, Jan Jacob Schuringa, Tom van Meerten, Gerwin Huls, Edwin Bremer